Sepsis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Sepsis Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The sepsis therapeutics market is projected to register a CAGR of 7.6% over the forecast period.

The COVID-19 pandemic affected the treatment and diagnostics procedures other than COVID-19 which had a significant impact on the studied market. The COVID-19 virus was also added to the list of pathogens that cause sepsis. For instance, an article titled "Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19" published in Frontiers in Immunology Journal in February 2021 stated that both SARS-CoV-2 infection and sepsis shared many pathophysiological and clinical features. Managing COVID, in the beginning, followed the sepsis management guidelines. Most patients who were critically ill with COVID-19 developed sepsis, a significant threat to their survival. Overall, the COVID-19 pandemic is anticipated to have had a positive impact on the market studied.

Sepsis can result from an infection anywhere in the body, such as pneumonia, influenza, or urinary tract infections. The COVID-19 pandemic increased surveillance of the infectious virus among people. Various countries, along with testing for COVID-19 in the test sample given by the symptomatic patient, were also testing for influenza virus, which is a major reason of sepsis. The increased diagnosis of bacterial and viral infection is expected to affect the market in a positive way, as people became aware about the sepsis therapeutics and company activities also increased. Hence COVID-19 viral infection worldwide is bolstering the need to expedite the research and development activities to develop sepsis therapeutics and ultimately augmenting the market growth.

In addition, the increasing incidence of sepsis, high prevalence of sepsis in infants, and rise in the number of pipeline products, and a surge in research and development expenditures are actively affecting the growth of the studied market.

The engagement of pharmaceutical companies and healthcare institutions in research and development activities to develop a noval treatment for sepsis is projected to augment the market growth. For instance, in October 2021, Matinas BioPharma initiated dosing in phase 1 study of one of the first oral aminoglycoside antibiotic drugs MAT2501. The surge in clinical trial activities is likely to augment the market growth.

Additionally, the funding by the government to expedite research activities for sepsis management is likely to create awareness about the disease among the population and ultimately boost market growth. For instance, according to the Canadian Institutes of Health Research July 2020 report, the Government of Canada invested USD 5.7 million to support Sepsis Canada, a new national research network that is expected to improve the treatment and recovery of sepsis patients. 190 clinicians, scientists, and patient representatives from all over Canada came together as part of Sepsis Canada. Such initiatives are anticipated to augment the market growth.

Therefore, owing to the abovementioned factors, the studied market is anticipated to witness growth over the analysis period. however, a lack of an initial diagnostic test for identifying sepsis conditions and a lack of awareness are likely to impede the market growth.

Key Market TrendsCephalosporins Are Expected To Witness Growth Over The Forecast Period

Cephalosporins are divided into the first, second, third, and fourth generations. First-generation cephalosporins have more significant activity against gram-positive bacteria. The succeeding generations have increased activity against gram-negative bacteria.

The dominant share of the segment is attributed to the extensive usage of the drug class, individually or in combination with the other drugs. For instance, the research article titled "Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective" published in Frontiers in Medicine Journal in May 2021, stated that ceftobiprole medocaril is currently approved in Europe as an extended-spectrum cephalosporin for adult community-acquired and nosocomial, non-ventilator-associated pneumonia and skin and soft tissue infection (SSTIs), including diabetic foot infections. The segment is expected to grow due to the advantages of cephalosporins during the forecast period.

Additionally, according to an article titled "Sepsis Management in Southeast Asia: A Review and Clinical Experience" published in the Journal of Clinical Medicine in June 2022, a recent study conducted in Southeast Asian region reported that 48% of adults and 56% of children were affected with sepsis and severe sepsis. According to the study, sepsis affected 65% of ICU patients in India, and there was a 25% fatality rate, making it the Southeast Asian nation with the second-highest sepsis mortality rate. The high burden of sepsis worldwide and its fatal effects is projected to augment the use of cephalosporins to treat it which is ultimately projected to boost the segment growth.

The increasing product approvals, launches, and acquisitions by the key market players are expected to boost the segment's growth during the forecast period. For instance, in October 2021, Sandoz, a Novartis division, acquired GSK's cephalosporin antibiotics business. It now has the rights to three well-known brands (Zinnat, Zinacef, and Fortum) in more than 100 markets. Such company developments are projected to boost the segment growth.

North America is Expected to Dominate the Sepsis Therapeutics Market Over The Forecast Period

North America is expected to dominate the market owing to factors such as the high prevalence of sepsis, chronic illness, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the region.

The Providence Health Care September 2022 article stated that sepsis is most prominent in infants and children and affects 40,000 to 50,000 individuals each year in Canada and it is the 12th leading cause of death in Canada. The article also stated that according to the Canadian Sepsis Foundation USD 325 million is spent annually on treating sepsis in Canada. The large patient pool and high disease spending propel the region's market growth.

Additionally, according to the Centers for Disease Control and Prevention (CDC), 2022 update, at least 1.7 million adults in the United States suffer from sepsis. It also stated that 1 out of 3 people's deaths in a hospital is because of sepsis during that hospitalization. Sepsis cases in the United States have increased steadily and leading to the growth of the studied market in the region.

Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The sepsis therapeutics market is slightly consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Some of the companies currently dominating the market are F. Hoffmann-La Roche Ltd, Pfizer Inc., GSK Plc, Viatris Inc (Mylan Inc.), AbbVie Inc. (Allergan Pharmaceuticals International Limited), Endacea Inc., Adrenomed AG, and RegeneRx.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.